Abstract View

Author(s): Bhanu Sasank Pogadapula 1*1, Shailaja Pashikanti 22, Sandhya Jyothi Reddiboina 33, Abdelhadiadam Salih Dene 34, Dhana Sri Gandham 15, Sai Durga Roopavath 16, S V Kali Dinesh Kumar 47

Email(s): 1mebhanusasank@gmail.com, 2

Address:

    1. Student, Department of Pharmaceutics, A.U. College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, India, 530003. 2. Head of the Department, Department of Pharmaceutics, A.U. College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, India, 530003. 3. Research scholar, Department of Pharmaceutics, A.U. College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, India, 530003. 4. Student, Department of Regulatory affairs, A.U. College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, India, 530003.

Published In:   Volume - 5,      Issue - 9,     Year - 2026

DOI: https://doi.org/10.71431/IJRPAS.2026.5904  

 View HTML        View PDF

Please allow Pop-Up for this website to view PDF file.

ABSTRACT:
Cubosomes are nanostructured lipid carriers that are bicontinuous cubic liquid crystalline phases. They provide an innovative method of delivery of advanced drugs. Cubosomes have an inner honeycomb structure unlike conventional liposomes. The material is permeated by two distinct water channels and divided by a lipid bilayer. The structure increases the surface area and the amount of drug to be loaded in the cubosomes. This review explores the various cubic phase’s symmetries (Pn3m, Ia3d, Im3m) and its effect on drug-release kinetics. It makes a comparison on how to prepare it, where high-energy top-down homogenization is superseded by scalable, solvent-free bottom-up and microfluidic methods. The latest developments in surface functionalization to target delivery in the fields of oncology, ophthalmology, and dermatology are mentioned. The paper has addressed issues surrounding cubosomes in clinical applications, such as the fact that non-lamellar structures do not have standard stability tests and also regulatory challenges with the use of Generally Recognized As Safe (GRAS) excipients. The review proposes a landscape of balancing chemicals to the patient and promoting the use of cubosomes by synthesizing data on preclinical research and insights on the emerging clinical trials, making them a powerful instrument to adopt as part of precision medicine.

Cite this article:
Bhanu Sasank Pogadapula et al. Cubosomes: Structure, Preparation Methods, Characterization, and Pharmaceutical Applications. IJRPAS, September 2026; 5(9): 33-68.DOI: https://doi.org/https://doi.org/10.71431/IJRPAS.2026.5904


References not available.

Related Images:



Recent Images



Methyl Red in Materials Engineering: A Systematic Review of Physicochemical, Energetic and Technological Applications Using the PRISMA Methodology
Nature to Laboratory Translation of Indole Scaffolds: Integrating Natural Product Diversity, Sustainable Synthesis, and Evidence Guided Medicinal Chemistry
Antidiuretic Hormone Deficiency and Central Diabetes Insipidus (Arginine Vasopressin Deficiency): Pathophysiology, Etiology, and Contemporary Management Strategies
Mechanistic Evaluation of Acalypha hispida in Psoriasis Using Network Pharmacology and In-vivo Experimental Models
Formulation and Evaluation of Solubility enhanced Aripiprazole Oro Dispersible Film for the improved patient compliance
LipoEdge™ Liposomal Zinc by WBCIL: From Critical Quality Attributes to Bioavailability Validation and Formulation Applications
Network Pharmacology: A Systems Biology Approach to Drug Discovery and Disease Mechanisms
Artificial Intelligence in Pharmaceutical Formulation Development: From Trial-and-Error to Data-Driven Design
Evaluation of In-Vitro Anti-Diabetic Activity And   Antioxidant Activity In Ethanolic and Hydroalcoholic Extract of leaves of Gymnema Sylvestre
Molecular Docking Approaches in Antibacterial Drug Discovery: Computational Insights into Natural Compounds

Tags